IMMY

Our Mission: Saving Lives One Diagnostic at a Time Our Vision: To drastically reduce mortality caused by infectious diseases through increased use of affordable diagnostics. IMMY is a US-based organization founded in 1979 with a focus in mycology, or the study of fungi. IMMY manufactures, markets, and distributes innovative lines of diagnostic tests and reagents for infectious diseases. Above all, we aim to raise the standard of healthcare for patients all over the world. Building Something Great IMMY is committed to building a diverse and empowered team. While individually we are unique, together we have built the foundation of our company on the shared values of compassion, integrity, innovation, simplicity, customer focus, and teamwork. IMMY is recognized by The Oklahoman as a Top Workplace and by the Potts Family Foundation as a Family Positive Workplace. Rapid Growth Potential Distinguished as one of the most successful biotech companies in Oklahoma, IMMY has experienced a tremendous amount of success in recent years. We recently built a new company headquarters in Norman, OK, and quadrupled its space. We have been recognized by Metro 50 as one of the top 50 fastest growing companies in the Oklahoma City Metro. This is an opportunity to shape a company on rise in the diagnostic industry. Innovation is in Our DNA IMMY has released several outstanding products in recent years, and each one is positively impacting the clinical outcomes of patients all over the world. IMMY’s flagship diagnostic test, the CrAg® LFA, is consistently proven to save thousands of immune-compromised patients’ lives each year. In 2020 we launched IMMYLabs and IMMY Tech Group in response to the COVID-19 pandemic to provide Oklahomans with efficient testing and vaccination services. This innovation and dedication to patient care earned recognition from the governor and several state agencies. In 2022 IMMY was also named 405 Business Magazine’s Biotech Innovator of the Year.